TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03761121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wave-CAIPI
Description: wave-CAIPI technology, a data acquisition / reconstruction scheme designed to optimally exploit available information in modern multi-channel receivers and in multi-contrast/time-series data for improved image encoding

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wave-CAIPI
Description: wave-CAIPI technology, a data acquisition / reconstruction scheme designed to optimally exploit available information in modern multi-channel receivers and in multi-contrast/time-series data for improved image encoding
Study: NCT03079336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation - SOTA
Description: The implementation of an evidence-based treatment is largely principle-based - allowing considerable therapeutic flexibility in determining and timing of different treatment aspects. In this condition progress, subtle changes and sudden gains may be an explicit topic and there is no restraint to avoid such topics. However, the therapists are not obligated to take a systematized focus on potential subtle changes and they may use the timing of the sessions to involve the patients into the other tasks of therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation - Prolonged focus on changes
Description: Systematized sequence of exploration of subtle changes at a prolonged check-in phase: (1) the precise change situation, (2) related emotional states, (3) related helpful thoughts and self-verbalizations, (4) reinforcement of generalized self-efficacy and treatment motivation, (5) benefit for the upcoming session goals (Flückiger, Grosse Holtforth, et al. 2013, 2014).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mastery your Anxiety and Worry (MAW)
Description: In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.~The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mastery your Anxiety and Worry (MAW)
Description: In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.~The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment.
Study: NCT02047604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN-300 0.5 mg/kg QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN-300 1.0 mg/kg QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN-300 2.0 mg/kg QOW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN-300 4.0 mg/kg QOW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN-300 4.0 mg/kg QW

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03643523

Intervention type: DIAGNOSTIC_TEST
Intervention: Albumine detection
Description: Control of serum albumine levels in postoperatori of colorectal surgery
Study: NCT00377663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AsthmaNet
Description: The AsthmaNet Web site will provide parents of children in the AsthmaNet group with individualized clinical information regarding their child's asthma care and with decision-making aids that they can share with their child's doctor. The web site will also prompt parents to make additional doctor appointments, as needed, to discuss their child's condition.
Study: NCT02436512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:~* (Dose 1): 5 ppm inhaled nitric oxide for 15 minutes~* (Dose 2): 40 ppm inhaled nitric oxide for 15 minutes
Study: NCT01314859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: * Oral Treatment with Nifedipine capsules (10mg)~  * Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).~ * Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.~* Maximum Duration of the treatment: 48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atosiban
Description: * Intravenously Treatment with Atosiban (7.5mg/ml)~  * Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.~ * Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.~* Maximum Duration of the treatment: 48 hours.
Study: NCT02566551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PAE
Description: Embolization of the prostate with gelatin embolization spheres via microcatheterization of the prostatic arteries.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelatin microspheres
Description: Gelatin embolization microspheres (300-500 microns) will be used as embolic material for the prostatic artery embolization (PAE) protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TURP
Description: Bipolar transurethral resection of the prostate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar electrosurgery generator
Description: A bipolar electrosurgery generator will be used to perform transurethral resection of the prostate (TURP)
Study: NCT00016094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03387800

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic health education messages
Description: Messages containing basic health education materials, including perceived severity of smoking, perceived benefit of smoking cessation and tips on resisting situational temptations will be sent to the participants of both arms through WeChat after randomization takes place.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic health education messages
Description: Messages containing basic health education materials, including perceived severity of smoking, perceived benefit of smoking cessation and tips on resisting situational temptations will be sent to the participants of both arms through WeChat after randomization takes place.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeChat interactive peer support group
Description: Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
Study: NCT03645200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib combined with Apatinib
Description: Fluzoparib :~40mg.bid, morning and evening each time, interval of 12 hours or so, the first oral administration 72 hours later~Apatinib :~250mg or 500mg take one day, 72 hours later, the continuous drug delivery phase (B-C1D1) was entered into the Fluzoparib, that is, the Fluzoparib capsule with 40mg.bid, every morning and evening, each time, interval of 12 hours, the Apatinib tablets daily with the Fluzoparib capsule with the same service, fixed doses of 250mg or 500mg, daily. Continuous drug delivery for 28 days for one cycle
Study: NCT02772003

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Electroporation-Mediated Plasmid DNA Vaccine Therapy
Description: Undergo electroporation
Study: NCT04335344

Intervention type: OTHER
Intervention: Observation of suPAR plasma and salivary levels
Description: Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease

Intervention type: OTHER
Intervention: Observation of suPAR plasma and salivary levels
Description: Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease

Intervention type: OTHER
Intervention: Observation of suPAR plasma and salivary levels
Description: Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease

Intervention type: OTHER
Intervention: Observation of suPAR plasma and salivary levels
Description: Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease
Study: NCT04483804

Intervention type: COMBINATION_PRODUCT
Intervention: Endocrine therapy
Description: Endocrine therapy

Intervention type: COMBINATION_PRODUCT
Intervention: Endocrine therapy
Description: Endocrine therapy
Study: NCT02605512

Intervention type: OTHER
Group type: OTHER
Intervention: Subclinical cardiac lesions and biomarkers
Description: Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma
Study: NCT02466308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAM Ultrasound Diathermy Device
Study: NCT04577092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm-up exercise
Description: In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm-up exercise
Description: In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor-Cognitive exercise
Description: After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor-Motor exercise
Description: participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cool-down exercise
Description: In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cool-down exercise
Description: In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
Study: NCT05458349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acellular dermis
Study: NCT02905305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour Advance electrode with controlled dose of dexamethasone base
Description: The Combined Device consists of a standard cochlear implant receiver-stimulator coupled to a Contour Advance electrode loaded with a controlled dose of dexamethasone base.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contour Advance electrode
Description: Standard Contour Advance electrode
Study: NCT02897141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health Management App with symptom strategies
Description: The mVIP group will receive a Health Management App with symptom strategies. A mobile app which includes symptom strategies from the UCSF symptom management manual.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control App
Description: The attention control group will receive an app which asked them about their symptoms but did not provide symptoms strategies
Study: NCT01435668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Description: Patients receive an information leaflet plus a referral to a psychologiste. BMI is provided by the psychologist. BMI consists in a first face-to-face interview (35-45 minutes) plus a telephone interview, at 1 and 2 months. Minors' parents are also invited to attend the BMI session.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Simple written advice
Description: Patients receive an information leaflet.
Study: NCT01790906

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RSD
Description: Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD .once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster,Diamond Bar,California)was introduced into each renal artery.then was maneuvered within the renal artery to allow energy delivery in a circumferential,longitudinally staggered manner to minimize the chance of renal artery stenosis.About six to nine ablation at 10W for 1 min each were performed in both renal arteries.during ablation, the catheter system monitored tip temperature and impedance,altering radiofrequency energy delivery in response to predetermined algorithm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional therapy
Description: Optimizing drug therapy,included angiotensin-converting enzyme inhibitors,aldosterone antagonist,beta-receptor blockers,diuretic,digoxin and so on.The patients with chronic heart failure ,whos'condition need for CRT-D(cardiac resynchronization therapy )/ICD(implantable cardioverter-defibrillator),are considered to implant CRT/ICD .CRT is abbreviation for cardiac resynchronization therapy ,ICD is defined for Implantable Cardioverter defibrillator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Optimizing drug therapy,included angiotensin-converting enzyme inhibitors,aldosterone antagonist,beta-receptor blockers,diuretic,digoxin and so on.The patients with chronic heart failure ,whos'condition need for CRT-D(cardiac resynchronization therapy )/ICD(implantable cardioverter-defibrillator),are considered to implant CRT/ICD .CRT is abbreviation for cardiac resynchronization therapy ,ICD is defined for Implantable Cardioverter defibrillator.
Study: NCT00501891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab administered intravenously 10mg/kg every other week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic Temozolomide
Description: Temozolomide 50mg/m2 given orally on a daily basis.
Study: NCT01127438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fospropofol disodium Subgroup 1 Lower Dose
Description: Dose of Initial IV (Titration) Bolus 6.5mg/kg) (administered to Subgroup 1, Weight \< 60 kg and Age \< 65 years and ASAI and II)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fospropofol disodium Subgroup 1 Approved Dose
Description: (Dose of Initial IV (Titration) Bolus 385mg) (Administered to Subgroup 1, Weight \<60 kg and Age \<65 years and ASAI and II)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fospropofol disodium Subgroup 2 Lower Dose
Description: Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (administered to Subgroup 2, Weight \< 60 kg and Age \>/=65 years and ASA 3 or 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fospropofol disodium Subgroup 2 Approved Dose
Description: (Dose of Initial IV (Titration) Bolus 297.5mg) (Administered to Subgroup 2, Weight \<60 kg and Age \>/=65 years and ASA 3 or 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fospropofol disodium Subgroup 3 Lower Dose
Description: (Dose of Initial IV (Titration) Bolus 3.9mg/kg) (Administered to Subgroup 3, Weight \>/= 60 kg and Age \>/= 65 years and ASA 3 or 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fospropofol disodium Subgroup 3 Approved Dose
Description: Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (Administered to Subgroup 3, Weight \>/= 60 kg and Age \>/= 65 years and ASA 3 or 4
Study: NCT04369469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Weight-based doses of ravulizumab were administered intravenously on Days 1, 5, 10, and 15.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BSC
Description: Participants received medications, therapies, and interventions per standard hospital treatment protocols.

Intervention type: OTHER
Group type: OTHER
Intervention: BSC
Description: Participants received medications, therapies, and interventions per standard hospital treatment protocols.
Study: NCT02772003

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HCV DNA Vaccine INO-8000
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rocakinogene Sifuplasmid
Description: Given IM
Study: NCT03059940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
Study: NCT02707640

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo, oral administration, three times daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine, 600 mg, oral administration, three times daily for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.

Intervention type: DRUG
Group type: OTHER
Intervention: Pirfenidone
Description: Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.
Study: NCT00555438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux 1.5 mg/day
Description: Subcutaneous injection of fondaparinux 1.5 mg/l after major orthopaedic surgery
Study: NCT00690638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHX1149T
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHX1149T
Description: 400 mg
Study: NCT03059940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Dose Computed Tomography Scan
Description: Participants have a CT scan of chest to look for signs of lung cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Dose Computed Tomography Scan
Description: Participants have a CT scan of chest to look for signs of lung cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Dose Computed Tomography Scan
Description: Participants have a CT scan of chest to look for signs of lung cancer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Making + Video
Description: Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Making + Video
Description: Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.
Study: NCT00690638

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02536859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
Study: NCT00996567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux)
Description: Patients will be treated with standard chemotherapy (4-6 cycles), combined with weekly administration of Cetuximab (Erbitux) until disease progression.
Study: NCT03059940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Making + Video
Description: Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation Counseling
Description: Brief cessation counseling given by LDCT provider.
Study: NCT03014752

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical ketogenic diet
Description: The classical ketogenic diet with a ratio of 4 to 1 (4:1), each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Atkins diet
Description: The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
Study: NCT03059940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation Counseling
Description: Brief cessation counseling given by LDCT provider.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation Counseling
Description: Brief cessation counseling given by LDCT provider.